Metabolic syndrome in Spanish patients with psoriasis needing systemic therapy: Prevalence and association with cardiovascular disease in PSO-RISK, a cross-sectional study

2014 ◽  
Vol 26 (4) ◽  
pp. 318-325 ◽  
Author(s):  
I. Belinchón ◽  
F. Vanaclocha ◽  
P. de la Cueva-Dobao ◽  
P. Coto-Segura ◽  
J. Labandeira ◽  
...  
Author(s):  
Nindia Sugih Arto ◽  
Adi Koesoema Aman ◽  
Dharma Lindarto

The hyperactivity of platelet had been seen in patients with metabolic syndrome which can be caused by several factors, such as:insulin resistance, obesity, dyslipidemia and hypertension. The hyperactivity of platelet leads to its aggregation that can be increased therisk of cardiovascular disease. This study is aimed to know the platelet aggregation and mean platelet volume in patients with metabolicsyndrome and obesity by determination 30 patients were choosen for this cross sectional study, those whom attended to the laboratoryand policlinic at H. Adam Malik Medan Hospital, between May 2013 until August 2013. The diagnosis used of metabolic syndromecriteria established by the International Diabetic Federation 2005. From the 30 patients with 15 metabolic syndrome and 15 obesity,four patients were excluded because of their tryglyceride were more than 200 mg/dL. There is no significant differences between theplatelet aggregation with the agonist adenosin difosfat (ADP) in patient with metabolic syndrome and obesity. And there is no significantdifferences of the mean platelet volume values between the metabolic syndrome (9.6±0.93) and the obesity group (9.73±0.74), with pvalue 0.846. Based on this study there is no significant differences between the platelet aggregation and the Mean Platelet Volume values(MPV) in the metabolic syndrome and the obese group


2019 ◽  
Vol 9 (2) ◽  
pp. 87-90
Author(s):  
Karanam Madhuri ◽  
◽  
Rishi Kumar Venkatachalam ◽  
A Nasreen Begum ◽  
Shamsheer Khan P ◽  
...  

2020 ◽  
Author(s):  
Mahshid Shahavandi ◽  
Hossein Shahinfar ◽  
Nastaran payande ◽  
Fatemeh Sheikhhossein ◽  
Kurosh Djafarian ◽  
...  

2021 ◽  
Vol 10 (13) ◽  
pp. 2812
Author(s):  
Cristina Bellarosa ◽  
Giorgio Bedogni ◽  
Annalisa Bianco ◽  
Sabrina Cicolini ◽  
Diana Caroli ◽  
...  

As in adults, obesity also plays a central role in the development of metabolic syndrome (MS) in children. Non-alcoholic fatty liver disease (NAFLD) is considered a manifestation of MS. Not only MS but also NAFLD seem to be inversely associated with serum bilirubin concentrations, an important endogenous tissue protector when only mild elevated. The aim of the study was to evaluate the association between serum bilirubin levels and the prevalence of MS and NAFLD in Italian obese children and adolescents. A retrospective cross-sectional study was performed in 1672 patients aged from 5 to 18 years. Clinical and laboratory parameters were assessed. NAFLD was measured by liver ultrasonography. The study was approved by the Ethical Committee of the Istituto Auxologico Italiano (research project code 1C021_2020, acronym BILOB). MS was present in 24% and fatty liver (FL) in 38% of this population. Bilirubin was not associated with FL and MS as a whole, but it was inversely associated only with selected components of MS, i.e., large WC, high blood pressure and high triglycerides. Our data suggest that bilirubin is not protective against MS and NAFLD in the presence of severe obesity.


Sign in / Sign up

Export Citation Format

Share Document